CN114671876B - Novel theophylline compound, isomer or salt, preparation method and application thereof - Google Patents
Novel theophylline compound, isomer or salt, preparation method and application thereof Download PDFInfo
- Publication number
- CN114671876B CN114671876B CN202210448131.0A CN202210448131A CN114671876B CN 114671876 B CN114671876 B CN 114671876B CN 202210448131 A CN202210448131 A CN 202210448131A CN 114671876 B CN114671876 B CN 114671876B
- Authority
- CN
- China
- Prior art keywords
- substituted
- unsubstituted
- preparation
- compound
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a compound shown in a formula (I), or stereoisomers, geometric isomers, tautomers, oxynitride compounds, hydrates, solvent compounds, metabolites or pharmaceutically acceptable salts of the compound shown in the formula (I). The invention also provides application of the compound, stereoisomer or pharmaceutically acceptable salt thereof in preparing medicaments for treating and/or preventing diseases related to the TRPA1 receptor, in particular to application in preparing medicaments for treating and/or preventing cough, asthma, pain and sleep apnea.
Description
Technical Field
The invention relates to the field of pharmaceutical chemistry, in particular to application of novel theophylline compounds or salts and isomers thereof, a preparation method thereof and a pharmaceutical composition thereof in preparation of drugs for treating and/or preventing diseases related to TRPA1 receptors, especially in treatment and/or prevention of respiratory diseases and nervous system diseases.
Background
Transient receptor potential (Transient Receptor Potential, TRP) channels are a non-selective cation channel. TRP ion channels in mammals can be divided into 7 subfamilies, TRPC (7 members), TRPM (8 members), TRPV (6 members), TRPA (ANKTM 1, unique member), TRPML (3 members), TRPP (5 members) and TRPN, based on TRP sequence homology. The TRP family is involved in a variety of cellular functions including sensory perception and signal transduction. Among them, TRPA1 receptors are associated with temperature, pain sensation, hyperalgesia and neurogenic inflammation.
TRPA1 is widely found in trigeminal nerves, dorsal roots, ganglion, expressed on primary sensory neurons of aδ and C fibers. Expression is also on non-neural cells such as inner ear hair cells, intestinal chromaffin cells, vascular endothelial cells, dental pulp fibroblast keratinocytes, islet cells, etc. The channel can be activated by noxious cold stimulus below 17 ℃, a series of chemical substance stimulus and inflammatory medium, generates transmembrane voltage change mainly of calcium ion inflow, participates in cold formation of noxious cold stimulus, and has the functions of regulating inflammatory reaction, apoptosis necrosis and mediating pain. Recent studies indicate that the receptor for TRPA1 is also a "switch" for coughing. Activation of TRPA1 receptors is therefore associated with a variety of diseases, such as showing significant therapeutic effects on pain, neuralgia, asthma, airway inflammation, bronchoconstriction and cough.
Among them, cough is one of the most common symptoms clinically. There is currently no approved drug for the treatment of chronic cough. Common antitussive therapeutic agents include codeine, dextromethorphan, etc., but central antitussive agents often have side effects such as constipation and somnolence. Pain is one of the most common pain in humans and one of the most common and intolerable symptoms in the clinic. The incidence of world pain is about 35-45%, and the incidence of the elderly is high, about 75-90%. The therapeutic drugs mainly comprise two types, one type is COX inhibitor (weak analgesic effect and relatively high safety), and the other type is opioid receptor agonism (strong analgesic effect, constipation, addiction and respiratory depression), and each type has advantages and disadvantages, and the clinical requirements cannot be met yet. In addition, about 16% of diabetics develop painful diabetic neuropathy. Drugs for the treatment of painful DPN mainly include tricyclic antidepressants, selective 5-hydroxytryptamine and norepinephrine reuptake inhibitors, opioids and antiepileptics. And available treatment regimens are not completely palliative, nor are they effective in all patients, with more than 50% pain relief being available to only about one third of patients. Accordingly, TRPA1 antagonists are potential therapeutic drugs for a variety of diseases, and there is a great unmet clinical need in the fields of pain, asthma, cough, etc.
TRPA1 antagonists are currently in clinical use in only two varieties, ISC-17536 at stage 2 (diabetic peripheral neuropathy, pain, respiratory disease) and LY-3526318 at stage 1 (pain). The IC50 value of ISC-17536 at inhibiting calcium current through TRPA1 is about 70 nM. The final point is not reached in European clinical studies of refractory cough, and the antagonism IC50 of LY-3526318 to TRPA1 is 5-6 uM, and the activity is weak. Therefore, there is a greater need in the clinic for antagonists with high activity on TRPA1, providing patients with a higher activity, safer drug selection opportunities, and great market and academic value in developing TRPA1 antagonists.
Disclosure of Invention
The compound is a novel theophylline compound, and most of the example compounds show good cough relieving effect and TRPA1 in vitro affinity in animals. In the cough test of mice, when 60mg/kg of the compound of the invention is orally administered, the compound has extremely strong cough relieving effect, and has statistical significance compared with a model group.
In one aspect, the present invention provides a compound of formula (i), a stereoisomer or a pharmaceutically acceptable salt thereof:
wherein, the liquid crystal display device comprises a liquid crystal display device,
ring A is selected from a substituted or unsubstituted 5-membered heterocycle, a substituted or unsubstituted 7-12 membered aromatic heterocycle, or a substituted or unsubstituted benzene; preferably, ring a is selected from a substituted or unsubstituted 5 membered aromatic heterocycle, or a substituted or unsubstituted benzene;
R 1 selected from the group consisting of hydrogen, deuterium, hydroxy, halogen, cyano, nitro, substituted or unsubstituted amino, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkylthio, substituted or unsubstituted cyclic amino, C3-C6 cyclic alkyl, C1-C3 perfluoroalkyl, C1-C3 perfluoroalkoxy, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aralkyl, substituted or unsubstituted heteroaryl, substituted or unsubstitutedHeteroaralkyl, substituted or unsubstituted heterocycloalkyl, - (CH 2 )fNR 2 R 3 、—O-(CH 2 )fN R 2 R 3 、—C(=O)fNR 2 R 3 Or a carboxyl group, wherein:
f is selected from integers from 1 to 4;
each R 2 Independently selected from hydrogen or lower alkyl;
each R 3 Independently selected from hydrogen, lower alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl.
Further, the structure of the compound, stereoisomer or pharmaceutically acceptable salt shown in the formula (I) is defined as follows:
ring a is selected from substituted or unsubstituted benzene, substituted or unsubstituted thiazole, substituted or unsubstituted isothiazole, substituted or unsubstituted oxazole, substituted or unsubstituted isoxazole, substituted or unsubstituted thiadiazole, substituted or unsubstituted oxadiazole, substituted or unsubstituted imidazole, substituted or unsubstituted pyrazole, substituted or unsubstituted furan, substituted or unsubstituted thiophene, substituted or unsubstituted pyrrole, substituted or unsubstituted 1,2, 3-triazole, or substituted or unsubstituted 1,2,4 triazole; preferably, ring a is selected from substituted or unsubstituted benzene, substituted or unsubstituted thiazole, substituted or unsubstituted isothiazole, substituted or unsubstituted oxazole, substituted or unsubstituted isoxazole, substituted or unsubstituted thiadiazole, or substituted or unsubstituted oxadiazole;
R 1 selected from hydrogen, deuterium, hydroxy, halogen, cyano, nitro, substituted or unsubstituted amino, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted alkylthio, substituted or unsubstituted 3-to 10-membered cyclic amino, C3-to C6-cyclic alkyl, C1-to C3-perfluoroalkyl, C1-to C3-perfluoroalkoxy, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aralkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaralkyl, or substituted or unsubstituted heterocycloalkyl.
Further, R is as described above 1 Selected from hydrogen, deuterium, and hydroxyA group, halogen, cyano, nitro, C1-C6 alkyl, trifluoromethyl, trifluoromethoxy, difluoromethyl, difluoromethoxy, or optionally selected from the following rings:
wherein:
x is selected from: o, NH or CHR 7 ；
Each R 4 、R 5 、R 6 、R 7 Independently selected from the group consisting of: hydrogen, halogen, hydroxy, amino, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, substituted or unsubstituted heterocycle, substituted or unsubstituted lower alkylamino, substituted or unsubstituted alkanoylamino, substituted or unsubstituted ester group, C3-C6 cyclic alkyl, C1-C3 perfluoroalkyl, C1-C3 perfluoroalkoxy or carboxyl;
additionally or alternatively, two R's attached to the same ring carbon 4 Or two R 5 Or two R 6 Substituents may together form oxo (i.e.: =o) or C3-C7 spirocyclic groups; and additionally or alternatively, two R's attached to different ring carbons 4 Or two R 5 Or two R 6 Substituents may together form a ring, wherein two R 6 The rings formed when taken together have from 4 to 7 ring atoms, including from 0 to 3 ring heteroatoms;
n is an integer from 0 to 4;
a is selected from integers from 0 to 3;
b. c is independently selected from integers from 0 to 2;
m and p are independently selected from integers of 1 to 3;
q, r are independently integers selected from 0 to 3.
Further, R is as described above 1 Selected from hydrogen, halogen, methyl, trifluoromethyl, trifluoromethoxy, difluoromethyl, difluoromethoxy, C1-C6 alkyl, or is selected from 1 to 2R 8 Substituted ring:
wherein each R 8 Independently selected from the group consisting of: hydrogen, halogen, hydroxy, amino, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, substituted or unsubstituted heterocycle, substituted or unsubstituted lower alkylamino, substituted or unsubstituted lower alkanoylamino, substituted or unsubstituted ester group, C3-C6 cyclic alkyl, C1-C3 perfluoroalkyl, C1-C3 perfluoroalkoxy or carboxyl.
Further, R is as described above 8 Selected from the group consisting of: hydrogen, halogen, hydroxy, amino, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylamino, C3-C6 cyclic alkyl, C1-C3 perfluoroalkyl or C1-C3 perfluoroalkoxy; preferably, R is as defined above 8 Selected from the group consisting of: hydrogen, halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C3 perfluoroalkyl or C1-C3 perfluoroalkoxy.
Further, substituents of the above ring a include, but are not limited to: hydrogen, halogen, hydroxy, amino, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, substituted or unsubstituted heterocycle, substituted or unsubstituted alkylamino, substituted or unsubstituted alkanoylamino, substituted or unsubstituted ester group, C3-C6 cyclic alkyl, C1-C3 perfluoroalkyl, C1-C3 perfluoroalkoxy, or carboxyl.
Further, the substituents of the ring A are selected from: hydrogen, halogen, hydroxy, amino, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylamino, C3-C6 cycloalkyl, C1-C3 perfluoroalkyl or C1-C3 perfluoroalkoxy.
Further, the compounds of formula (i), stereoisomers or pharmaceutically acceptable salts thereof, include, but are not limited to, the following:
。
further, the compounds of the present invention also include geometric isomers, tautomers, oxynitrides, hydrates, solvates, metabolites or prodrugs of the above-mentioned compounds.
Still further, the hydrogen in the above compounds, stereoisomers, pharmaceutically acceptable salts, geometric isomers, tautomers, oxynitrides, hydrates, solvates, metabolites or prodrugs thereof may be substituted with one or more deuterium.
Further, the invention provides a pharmaceutical composition of the compound, the stereoisomer and the pharmaceutically acceptable salt thereof, which is characterized by further comprising pharmaceutically acceptable auxiliary materials.
In another aspect, the present invention also provides the use of the above-mentioned compounds, stereoisomers thereof, and pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment and/or prevention of diseases associated with TRPA1 receptors.
Further, the above-mentioned TRPA1 receptor-related diseases are selected from respiratory diseases or nervous system diseases; respiratory diseases are preferred.
Further, the above-mentioned TRPA1 receptor-related diseases are selected from cough, asthma, pain or sleep apnea; cough is preferred.
Term interpretation:
the "alkyl" includes straight-chain and branched alkyl groups.
The above "lower alkyl" is: C1-C16 straight or branched alkyl.
The definition of the alkyl moiety in the above "lower alkoxy", "lower alkylamino", "lower alkylthio", "lower alkanoylamino" is the same as the above "lower alkyl".
The above-mentioned "C1-C6 alkyl": refers to a straight or branched alkyl group having 1 to 6 carbon atoms, such as, for example: methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, n-hexyl, isohexyl.
The alkyl moiety in the "C1-C6 alkoxy" and the "C1-C6 alkylamino" is the same as the "C1-C6 alkyl".
The term "perfluoro" in the above-mentioned "C1-C3 perfluoroalkyl" means that hydrogen on the carbon atom of the alkyl group is substituted with fluorine. Such as trifluoromethyl, -CF 2 CF 3 、—CFCF 3 CF 3 、—CF 2 CF 2 CF 3 。
The term "perfluoro" in the above-mentioned "C1-C3 perfluoroalkoxy" is as defined above.
The "substituent" in the above "substituted or unsubstituted" is selected from the group consisting of, unless otherwise specified: hydrogen, halogen, hydroxy, amino, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, substituted or unsubstituted heterocycle, substituted or unsubstituted alkylamino, substituted or unsubstituted alkanoylamino, substituted or unsubstituted ester, C3-C6 cycloalkyl, C1-C3 perfluoroalkyl, C1-C3 perfluoroalkoxy, or carboxyl; preferably, the "substituents" are selected from: hydrogen, halogen, hydroxy, amino, substituted or unsubstituted C1-C6 alkyl.
The term "C1 to C16" means a compound containing 1 to 16 carbon atoms. Other similar writing methods are similarly explained.
The above-mentioned "3-to 10-membered cyclic amino group" is: a nitrogen-containing heterocyclic ring having 3 to 10 ring atoms; the heterocyclic ring includes, but is not limited to, a single ring, a bridged ring, at least 1 heteroatom in number, all heteroatoms being N, or comprising N and S and/or O. As part of the R1 substituent, this moiety is preferably a 5-to 8-membered cyclic amino group; more preferably a 5-to 6-membered cyclic amino group; most preferred is a 5 membered cyclic amino group.
The above "halogen" is: fluorine, chlorine, bromine.
The "pharmaceutically acceptable salts" include, but are not limited to, organic acid salts or inorganic acid salts; such acids include, but are not limited to, hydrochloric acid, sulfuric acid, benzenesulfonic acid, p-toluenesulfonic acid, 1, 5-naphthalenedisulfonic acid, trifluoroacetic acid, acetic acid, malic acid, tartaric acid, hydrobromic acid, and the like.
Such "solvates" include, but are not limited to, organic solvents or inorganic solvents, including, but not limited to, methanol, ethanol, acetone, heptane, and the like.
The "hydrates" include, but are not limited to, monohydrate, dihydrate, trihydrate, and the like.
The term "nitroxide" includes, but is not limited to, any or at least one nitrogen atom on the parent nucleus being oxidized to form an N.fwdarw.O bond.
The "pharmaceutically acceptable excipients" include, but are not limited to, pharmaceutically acceptable additives including, but not limited to, fillers, disintegrants, lubricants, solubilizers, binders, diluents, glidants, and the like.
The "pharmaceutical composition" includes, but is not limited to, the active ingredient and pharmaceutically acceptable excipients, which are formulated into a dosage form such as tablet, capsule, injection, microparticle, aerosol, ointment, etc. by conventional preparation means in the art. Routes of administration include, but are not limited to, oral, intravenous, and the like.
The beneficial effects are that: compared with the prior art, the invention has better cough relieving effect and higher safety.
Detailed Description
The present invention will be described in further detail with reference to the following examples and experimental examples, which are only for illustrating the technical scheme of the present invention, but not for limiting the present invention, and any equivalent substitution in the art according to the disclosure of the present invention shall fall within the scope of the present invention.
The compounds of the present invention, stereoisomers or pharmaceutically acceptable salts thereof may be prepared by the synthetic routes of the examples, and the conventional conditions of the reaction starting materials and reaction solvents may be adjusted according to the substituents or salt-forming requirements, which may be accomplished by one skilled in the art based on the present disclosure. In addition, the column chromatography of the present invention refers to silica gel column chromatography unless otherwise specified, and the eluting solvent may be a single or mixed eluting solvent determined by combining the reaction solvent with common knowledge or common means of a person skilled in the art.
The structure of the compound is nuclear magnetic resonance 1 H NMR) or liquid mass spectrometry (LC-MS).
The liquid chromatography-mass spectrometer (LC-MS) is Agilent G6120B (matched with liquid phase Agilent 1260); nuclear magnetic resonance apparatus 1 H NMR) of Bruker AVANCE-400 or Bruker AVANCE-800, nuclear magnetic resonance 1 H NMR) shift [ ]δ) Given in parts per million (ppm), the assay solvent is DMSO and the internal standard is tetramethylThe chemical shift of the alkylsilane (TMS) was 10 -6 (ppm) is given as a unit.
The term "room temperature" according to the invention means a temperature between 10 and 25 ℃.
Example 1: preparation of (S) -2- (1, 3-dimethyl-2, 6-dioxo-1, 2,3, 6-tetrahydro-7H-purin-7-yl) -N- (5- (4- (S) -2-methylpyrrolidin-1-yl) pyrimidin-5-yl) -1,3, 4-thiadiazol-2-yl) propionamide:
step one: preparation of methyl (S) -2-2- (1-methyl-2, 6-dioxo-3, 4,5, 6-tetrahydro-1H-purin-7 (2H) -yl) propionate
1-methyl-3, 4,5, 7-tetrahydro-1H-purine-2, 6-dione (747.7 mg,4.15 mmol) and K are added to a 25ml three-necked flask 2 CO 3 (0.573 g,4.15 mmol) DMF (7 mL) was stirred. Methyl (R) -2- (methylsulfonyloxy) propionate (0.5 g,3.2 mmoL) was added, the reaction was stirred at room temperature overnight, and the reaction was completed, followed by saturated NH 4 Cl (20 ml) was quenched. The resulting mixture was extracted with EA (3X 20 mL). The combined organic phases were washed with water (3X 50 mL) and brine. Anhydrous Na for organic phase 2 SO 4 Dried and concentrated. The residue was purified by chromatography (MeOH: dcm=1:100), the product was collected and concentrated to dryness to give the title product as a white solid (552 mg), yield 50% purity 97.89%.
ESI-MS:m/z= 267.1(M+H) + 。
Step two: preparation of (S) -2-2- (1-methyl-2, 6-dioxo-3, 4,5, 6-tetrahydro-1H-purin-7 (2H) -yl) propionic acid
Into a 25mL reaction flask was charged methyl (S) -2-2- (1-methyl-2, 6-dioxo-3, 4,5, 6-tetrahydro-1H-purin-7 (2H) -yl) propionate (0.35 g,1.31 mmol), dioxane (4 mL), 6N HCl (2 mL). The reaction was refluxed for 3h, cooled to room temperature, concentrated to dryness, added with 3ml of water, stirred in ice bath to precipitate a solid, filtered and dried to 250mg of a white solid product with a yield of 75.4% and a purity of 97.39%.
ESI-MS:m/z=253(M+H) + 。
Step three: preparation of (S) -N- (5-bromo-1, 3, 4-thiadiazol-2-yl) -2- (1, 3-dimethyl-2, 6-dioxo-1, 2,3, 6-tetrahydro-7H-purin-7-yl) propanamide
To a 25ml three-necked flask was added (S) -2-2- (1-methyl-2, 6-dioxo-3, 4,5, 6-tetrahydro-1H-purin-7 (2H) -yl) propionic acid (200 mg,0.8 mmol), 5-bromo-1, 3, 4-thiadiazol-2-amine (170 mg,0.8 mmol), acetonitrile (2 ml), NMI (197mg, 2.4 mmol), and the mixture was dissolved with stirring, TCFH (301 mg,1.2 mmol) was added in portions, and the mixture was reacted overnight at room temperature. And (3) adding EA after the reaction, extracting and washing with water, drying, concentrating and drying the organic phase, and passing through a silica gel column to obtain 220mg of a product with the yield of 66.98%.
ESI-MS:m/z=415.0(M+H) + 。
Step four: preparation of (S) -2- (2-methylpyrrolidin-1-yl) -5- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) pyrimidine
To a 50ml three-necked flask was added 2-chloropyrimidine-5-boronic acid pinacol ester (1.0 g,4.16 mmol), (S) -2-methylpyrrolidine (0.35 g,4.16 mmol), DMF (10 ml), cooled to-5℃and DIEA (1.65 g,12.5 mmol) was added dropwise with stirring, and the mixture was reacted overnight at room temperature. After the reaction, EA was added, followed by washing with water, and the organic phase was dried by drying, to give 1.0g of a product with a yield of 83.1% and used directly in the next step.
ESI-MS:m/z=290.1(M+H) + 。
Step five: preparation of (S) -2- (1, 3-dimethyl-2, 6-dioxo-1, 2,3, 6-tetrahydro-7H-purin-7-yl) -N- (5- (4- (S) -2-methylpyrrolidin-1-yl) pyrimidin-5-yl) -1,3, 4-thiadiazol-2-yl) propanamide
Into a 25ml three-necked flask was placed ((S) -N- (5-bromo-1, 3, 4-thiadiazol-2-yl) -2- (1, 3-dimethyl-2, 6-dioxo-1, 2,3, 6-tetrahydro-7H-purin-7-yl) propionamide (120 mg,0.29 mmol), (S) -2- (2-methylpyrrolidin-1-yl) -5- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) pyrimidine (125.7 mg,0.43 mmol), pd (dppf) Cl 2` C 2 HCl 2 (46 mg,0.056 mmol), DMF (1.5 ml), water (0.5 ml), cesium carbonate (281.6 mg,0.87 mmol), N 2 After three substitutions, the reaction was carried out by heating to 95℃for 6 hours. After the reaction, EA is added, water is used for extraction and washing, and the organic phase is dried by drying and concentration. Purification by silica gel chromatography (PE: ea=1:1→1:5), collecting the product, concentrating to dryness gave 70mg of a yellow solid product in a yield of 48.7% and a purity of 96.50%.
ESI-MS:m/z=497.2(M+H) + 。
1 H NMR (400 MHz, DMSO-d6) δ:12.20 (s, 1H), 8.78(s, 2H), 8.22 (d, 1H), 5.86 (d, 1H), 4.30 (s,1H), 3.59 (m, 1H), 3.46 (s, 3H), 3.19 (s, 3H),2.08 (s, 3H), 1.95 (s, 1H), 1.88 (d, 3H), 1.72 (s, 1H), 1.24 (d, 3H)。
Example 2: preparation of (S) -2- (1, 3-dimethyl-2, 6-dioxo-1, 2,3, 6-tetrahydro-7H-purin-7-yl) -N- (4- (2- (S) -2-methylpyrrolidin-1-yl) pyrimidin-5-yl) thiazol-2-yl) propanamide
Step one: preparation of (S) -4- (2- (2-methylpyrrolidin-1-yl) pyrimidin-5-yl) thiazol-2-amine
Into a 25ml three-necked flask was charged (S) -2- (2-methylpyrrolidin-1-yl) -5- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) pyrimidine (200 mg,0.69 mmol), 4-bromothiazol-2-amine (124 mg,0.69 mmol), pd (Ph) 3 P） 4 (80 mg,0.069 mmol), potassium carbonate (284 mg,2.07 mmol), dioxane (3 ml), water (0.6 ml), N 2 After three substitutions, the reaction was carried out by heating to 1055℃for 6 hours. After the reaction, EA was added, the mixture was washed by extraction with water, and the organic phase was dried by drying and concentrated, followed by passing through a silica gel column to obtain 100mg of a yellow oily product with a yield of 55.3%.
ESI-MS:m/z= 262.1(M+H) + 。
Step two: preparation of (S) -2- (1, 3-dimethyl-2, 6-dioxo-1, 2,3, 6-tetrahydro-7H-purin-7-yl) -N- (4- (2- (S) -2-methylpyrrolidin-1-yl) pyrimidin-5-yl) thiazol-2-yl) propanamide
Into a 25ml reaction flask was charged (136 mg,0.54 mmol), (S) -2-2- (1-methyl-2, 6-dioxo-3, 4,5, 6-tetrahydro-1H-purin-7 (2H) -yl) propionic acid (136 mg,0.54 mmol), (S) -4- (2- (2-methylpyrrolidin-1-yl) pyrimidin-5-yl) thiazol-2-amine (140 mg,0.54 mmol), HOBT (146 mg,1.08 mmol), dry pyridine (2 ml) and EDCI (206 mg,1.08 mmol) were added in portions and the reaction was stirred at room temperature overnight. At the end of the reaction, EA was added, extracted with water, washed, the organic phase was dried by drying, column purified by silica gel chromatography (DCM: meoh=100:1→100:5), the product was collected and concentrated to dryness to afford 80mg of a yellow solid product, 29.9% yield, 98.40% purity.
ESI-MS:m/z=496.2(M+H) + 。
1 HNMR (400 MHz, DMSO-d6) δ: 12.81 (s, 1H), 8.80 (s, 2H), 8.32 (s, 1H), 7.48 (s, 1H), 5.76(m, 1H), 4.26 – 4.20 (m, 1H), 3.56 (d, 1H), 3.48 (d, 1H), 3.44 (s, 3H), 3.16 (s, 3H), 2.05 – 2.00 (m, 2H), 1.85 (d, 4H), 1.66 (d, 1H), 1.19 (d, 3H)。
Example 3: preparation of (S) -2- (1, 3-dimethyl-2, 6-dioxo-1, 2,3, 6-tetrahydro-7H-purin-7-yl) -N- (4- (4- (S) -2-methylpyrrolidin-1-yl) pyrimidin-5-yl) -5-methylthiazol-2-yl) propanamide
The preparation method is the same as that of example 2, the 4-bromothiazole-2-amine in the first step is replaced by equimolar 4-bromo-5-methylthiazole-2-amine, and the second step is the same, so that the title compound is obtained as a yellow solid, and the two-step reaction yield is: 30.5% and purity 98.02%.
ESI-MS:m/z=510.2(M+H) + 。
1 HNMR (400 MHz, DMSO-d6) δ:12.75 (s, 1H), 8.56 (s, 2H), 8.22 (d, 1H), 5.88 (d, 1H), 4.30 (s,1H), 3.59 (m, 1H), 3.46 (s, 3H), 3.19 (s, 3H), 2.48 (s, 3H),2.08 (s, 3H), 1.95 (s, 1H), 1.88 (d, 3H), 1.72 (s, 1H), 1.24 (d, 3H)。
Example 4: preparation of (S) -2- (1, 3-dimethyl-2, 6-dioxo-1, 2,3, 6-tetrahydro-7H-purin-7-yl) -N- (3- (2- (S) -2-methylpyrrolidin-1-yl) pyrimidin-5-yl) phenyl) propanamide
The preparation method is the same as that of example 2, the 4-bromothiazol-2-amine in the first step is replaced by equimolar m-bromoaniline, the second step is the same, the title compound is obtained, and the yield of the two steps reaction: 25.3% and 97.22% purity.
ESI-MS:m/z=489.2(M+H) + 。
1 H NMR (400 MHz, DMSO-d6) δ:11.35 (s, 1H), 8.66 (s, 2H), 8.22 (d, 1H), 8.06 (t, 1H), 7.67(ddd, 1H), 7.51 (ddd, 1H), 7.39 (t, 1H), 5.85 (d, 1H), 4.30 (s, 1H), 3.59 (m, 1H), 3.46 (s, 3H), 3.19 (s, 3H), 2.08 (s, 3H), 1.95 (s, 1H), 1.88 (d, 3H), 1.72(s, 1H), 1.24 (d, 3H)。
Example 5: preparation of (S) -2- (1, 3-dimethyl-2, 6-dioxo-1, 2,3, 6-tetrahydro-7H-purin-7-yl) -N- (5- (2- (S) -2- (trifluoromethyl) pyrrolidin-1-yl) pyrimidin-5-yl) -1,3, 4-thiadiazol-2-yl) propionamide
Preparation method the same preparation method as in example 1 was followed by substituting equimolar (S) -2- (trifluoromethyl) pyrrolidine in step four to give the title compound as a yellow solid in yield: 35.1% and 97.9% purity.
ESI-MS:m/z= 551.2(M+H) + 。
1 HNMR (400 MHz, DMSO-d6) δ:11.16(s, 1H),8.87 (s, 2H), 8.22(d, 1H),5.82(q, 1H),5.12(t,1H),3.70(m, 2H),3.47(s, 3H),3.16(s，3H),2.10(m. 4H),1.88(d, 3H)。
Example 6: preparation of (S) -2- (1, 3-dimethyl-2, 6-dioxo-1, 2,3, 6-tetrahydro-7H-purin-7-yl) -N- (4- (4- (S) -2- (trifluoromethyl) pyrrolidin-1-yl) pyrimidin-5-yl) -5-methylthiazol-2-yl) propanamide
Preparation method the same preparation method as in example 1 was followed by substituting equimolar 4-bromo-5-methylthiazol-2-amine for 4-bromothiazol-2-amine in step one and equimolar (S) -2- (trifluoromethyl) pyrrolidine for (S) -2-methylpyrrolidine in step four to give the title compound in the yield: 43.6% and a purity of 97.26%.
ESI-MS:m/z=564.2(M+H) + 。
1 H NMR(400 MHz, DMSO-d6) δ: 12.21 (s, 1H),8.75 (s, 2H), 8.22 (d, 1H),5.82(q, 1H),5.12(t,1H),3.70(m, 2H),3.47(s, 3H),3.16(s, 3H),2.48 (s, 3H),2.10(m, 4H),1.88(d, 3H)。
Example 7: preparation of (S) -2- (1, 3-dimethyl-2, 6-dioxo-1, 2,3, 6-tetrahydro-7H-purin-7-yl) -N- (5- (4- (S) -2-methylpyrrolidin-1-yl) pyrimidin-5-yl) -1,3, 4-oxadiazol-2-yl) propanamide
Preparation method the same procedure as in example 2 was followed substituting equimolar amounts of 5-bromo-1, 3, 4-oxadiazol-2-amine for 4-bromothiazol-2-amine in step one to give the title compound in yield: 45.2% and purity 98.48%.
ESI-MS:m/z= 481.2(M+H) + 。
1 H NMR (400 MHz, DMSO-d6) δ:12.11 (s, 1H), 9.02(s, 2H), 8.29 (d, 1H), 5.56 (d, 1H), 4.30 (s,1H), 3.59 (m, 1H), 3.46 (s, 3H), 3.19 (s, 3H),2.08 (s, 3H), 1.95 (s, 1H), 1.88 (d, 3H), 1.72 (s, 1H), 1.24 (d, 3H)。
Example 8: preparation of (S) -2- (1, 3-dimethyl-2, 6-dioxo-1, 2,3, 6-tetrahydro-7H-purin-7-yl) -N- (4- (2- ((S) -2-methylpyrrolidin-1-yl) pyrimidin-5-yl) -5- (trifluoromethyl) thiazol-2-yl) propanamide
Preparation method the same procedure as in example 2 was followed substituting equimolar amounts of 4-bromo-5- (trifluoromethyl) thiazol-2-amine with 4-bromo-thiazol-2-amine in step one to give the title compound in yield: 52.7% and a purity of 98.06%.
ESI-MS:m/z=564.2(M+H) + 。
1 H NMR (400 MHz, DMSO-d6) δ:12.21 (s, 1H), 8.77(s, 2H), 8.27 (d, 1H), 5.80 (d, 1H), 4.30 (s,1H), 3.59 (m, 1H), 3.46 (s, 3H), 3.19 (s, 3H),2.08 (s, 3H), 1.95 (s, 1H), 1.88 (d, 3H), 1.72 (s, 1H), 1.24 (d, 3H)。
Example 9: preparation of (S) -2- (1, 3-dimethyl-2, 6-dioxo-1, 2,3, 6-tetrahydro-7H-purin-7-yl) -N- (5-fluoro-4- (4- (S) -2-methylpyrrolidin-1-yl) pyrimidin-5-yl) thiazol-2-yl) propanamide
Preparation of intermediate (S) -5-fluoro-4- (2- (2-methylpyrrolidin-1-yl) pyrimidin-5-yl) thiazol-2-amine
/>
10ml reaction flask was charged with (S) -4- (2- (2-methylpyrrolidin-1-yl) pyrimidin-5-yl) thiazol-2-amine (200 mg,0.77 mmol), acetonitrile (2.5 ml), cooled to-25℃and SelectFluor (328 mg,0.92 mmol) was added, TLC monitored until the starting material had reacted, the reaction was completed, water was added, DCM was used for extraction, the layers were separated and the organic phase was concentrated. Purification by silica gel column (PE: ea=8:2→1:2), collection of the product, concentration to dryness afforded 140mg of the product in 39.9% yield.
ESI-MS:m/z=280.1(M+H) + 。
Preparation method the same procedure as in example 2 was followed substituting equimolar (S) -5-fluoro-4- (2- (2-methylpyrrolidin-1-yl) pyrimidin-5-yl) thiazol-2-amine for (S) -4- (2- (2-methylpyrrolidin-1-yl) pyrimidin-5-yl) thiazol-2-amine in step two to give the title compound in yield: 45.7% and 97.46% purity.
ESI-MS:m/z= 514.2(M+H) + 。
1 H NMR (400 MHz, DMSO-d6) δ:12.21 (s, 1H), 8.77(s, 2H), 8.27 (d, 1H), 5.80 (d, 1H), 4.12 (s,1H), 3.77 – 3.67 (m, 1H), 3.62 – 3.51 (m, 1H), 3.46 (s, 3H), 3.38 (s, 3H), 2.01 – 1.83 (m, 2H), 1.87 – 1.76 (m, 1H),1.67 (d, 3H), 1.64 – 1.53 (m, 1H), 1.20 (d, 3H)。
Example 10: preparation of (S) -2- (1, 3-dimethyl-2, 6-dioxo-1, 2,3, 6-tetrahydro-7H-purin-7-yl) -N- (4- (2-methylpyrimidin-5-yl) thiazol-2-yl) propanamide
Preparation method the same procedure as in example 2 was followed substituting (S) -2- (2-methylpyrrolidin-1-yl) -5- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) pyrimidine in step one with equimolar 2-methylpyrimidine-5-boronic acid pinacol ester to give the title compound in yield: 58.9% and purity 98.55%.
ESI-MS:m/z= 427.1(M+H) + 。
1 H NMR (400 MHz, DMSO-d6) δ:12.10 (s, 1H),8.99 (s, 2H), 8.22 (d, 1H), 7.38 (s, 1H), 5.78 (d,1H), 3.46 (s, 3H), 3.38 (s, 3H), 2.46 (s, 3H), 1.67 (d, 3H)。
Example 11: preparation of (S) -2- (1, 3-dimethyl-2, 6-dioxo-1, 2,3, 6-tetrahydro-7H-purin-7-yl) -N- (4- (2- (piperidin-1-yl) pyrimidin-5-yl) thiazol-2-yl) propanamide
Preparation method the same preparation method as in example 1 was followed by substituting 5-bromo-1, 3, 4-thiadiazole-2-amine in step three with equimolar 4-bromothiazol-2-amine and substituting (S) -2-methylpyrrolidine in step four with equimolar piperidine hydrochloride to give the title compound as a yellow solid in yield: 55.8% and 97.86% purity.
ESI-MS:m/z= 496.2(M+H) + 。
1 H NMR (400 MHz, DMSO-d6) δ: 11.50 (s, 1H), 8.77 (s, 2H), 8.22 (d, 1H), 7.38 (s, 1H), 5.80(d,1H), 3.68 (m, 4H), 3.46 (s, 3H), 3.38 (s, 3H), 1.70 – 1.54 (m, 9H)。
Example 12: preparation of (S) -2- (1, 3-dimethyl-2, 6-dioxo-1, 2,3, 6-tetrahydro-7H-purin-7-yl) -N- (4- (2- (trifluoromethyl) pyrimidin-5-yl) thiazol-2-yl) propanamide
Preparation method the same procedure as in example 2 was followed substituting (S) -2- (2-methylpyrrolidin-1-yl) -5- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) pyrimidine in step one with equimolar 5- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -2- (trifluoromethyl) pyrimidine to give the title compound in the yield: 58.9% and purity 98.55%.
ESI-MS:m/z= 481.1(M+H) + 。
1 H NMR (400 MHz, DMSO-d6)δ: 12.31 (s, 1H),9.03 (s, 2H), 8.22 (d, 1H), 7.39 (s, 1H), 5.80 (d,1H), 3.46 (s, 3H), 3.38 (s, 3H), 1.87 (d, 3H)。
Example 13: preparation of (S) -2-N- (4- (2, 5-diazabicyclo [2.2.1] hept-2-yl) pyrimidin-5-yl) thiazol-2-yl) -2- (1, 3-dimethyl-2, 6-dioxo-1, 2,3, 6-tetrahydro-7H-purin-7-yl) propionamide
Preparation method the same procedure as in example 1 was followed substituting equimolar 4-bromothiazol-2-amine for 5-bromo-1, 3, 4-thiadiazol-2-amine in step three and equimolar tert-butyl 2, 5-diazabicyclo [2.2.1] heptane-2-carboxylate for (S) -2-methylpyrrolidine in step four to give 5- (5- (2- ((S) -2- (1, 3-dimethyl-2, 6-dioxo-1, 2,3, 6-tetrahydro-7H-purin-7-yl) propanamido) thiazol-4-yl) pyrimidin-2-yl) -2, 5-diazabicyclo [2.2.1] heptane-2-carboxylate and removing the Boc protecting group with trifluoroacetic acid to give the title compound in the yield: 45.9% and purity 98.63%.
ESI-MS:m/z= 509.2(M+H) + 。
1 H NMR (400 MHz, DMSO-d6) δ: 12.11 (s, 1H), 8.78 (s, 2H), 8.22 (d, 1H), 7.38 (s, 1H), 5.79(d,1H), 4.29 (m, 1H), 3.94 (m, 2H), 3.46 (s, 3H), 3.38 (s, 3H), 3.23 (m, 1H), 3.17 – 3.02 (m, 2H), 2.15 (m, 1H), 2.08 – 1.99 (m, 1H), 1.90 – 1.81 (m, 1H),1.67 (d, 3H)。
Example 14: preparation of (S) -2-N- (4- (2- (3, 8-diazabicyclo [3.2.1] Xin Tan-8-yl) pyrimidin-5-yl) thiazol-2-yl) -2- (1, 3-dimethyl-2, 6-dioxo-1, 2,3, 6-tetrahydro-7H-purin-7-yl) propionamide
Preparation method the same procedure as in example 1 was followed substituting equimolar 4-bromothiazol-2-amine for 5-bromo-1, 3, 4-thiadiazol-2-amine in step three and equimolar 3, 8-diazabicyclo [3.2.1] octane-3-carboxylic acid tert-butyl ester for (S) -2-methylpyrrolidine in step four to give 8- (5- (2- ((S) -2- (1, 3-dimethyl-2, 6-dioxo-1, 2,3, 6-tetrahydro-7H-purin-7-yl) propanamido) thiazol-4-yl) pyrimidin-2-yl) -3, 8-diazabicyclo [3.2.1] octane-3-carboxylic acid tert-butyl ester and removing the Boc protecting group with trifluoroacetic acid to give the title compound in yield: 45.9% and purity 98.63%.
ESI-MS:m/z= 523.2(M+H) + 。
1 H NMR(400 MHz, DMSO-d6) δ: 12.06 (s, 1H),8.75 (s, 2H), 8.22 (d, 1H), 7.38 (s, 1H), 5.75 (d,1H), 4.13 (m, 2H), 3.46 (s, 3H), 3.38 (s, 3H), 3.12 – 3.05 (m, 1H), 3.08 – 3.03 (m, 1H), 2.98 (m, 2H), 2.85 (m, 1H), 2.05 – 1.78 (m, 4H),1.67 (d, 3H)。
Example 15: preparation of (S) -N- (4- (2- (2-aza-1-yl) pyrimidin-5-yl) thiazol-2-yl) -2- (1, 3-dimethyl-2, 6-dioxo-1, 2,3, 6-tetrahydro-7H-purin-7-yl) propanamide
Preparation method the same preparation method as in example 1 was followed by substituting 5-bromo-1, 3, 4-thiadiazole-2-amine in step three with equimolar 4-bromothiazol-2-amine and substituting (S) -2-methylpyrrolidine in step four with equimolar heptaazomethine to give the title compound in yield: 65.9% and a purity of 98.77%.
ESI-MS:m/z= 510.2(M+H) + 。
1 H NMR (400 MHz, DMSO-d6) δ: 11.06 (s, 1H), 8.77 (s, 2H), 8.22 (d, 1H), 7.38 (s, 1H), 5.68(d, 1H), 3.56 (m, 4H), 3.46 (s, 3H), 3.38 (s, 3H), 1.78 – 1.64 (m, 7H), 1.63 – 1.49 (m, 4H)。
Example 16: preparation of (S) -2-N- (4- (2- (3, 6-diazabicyclo [3.1.1] hept-6-yl) pyrimidin-5-yl) thiazol-2-yl) -2- (1, 3-dimethyl-2, 6-dioxo-1, 2,3, 6-tetrahydro-7H-purin-7-yl) propionamide
Preparation method the same procedure as in example 1 was followed substituting equimolar 4-bromothiazol-2-amine for 5-bromo-1, 3, 4-thiadiazol-2-amine in step three and equimolar 6- (tert-butoxycarbonyl) -3, 6-diazabicyclo [3.1.1] heptane for (S) -2-methylpyrrolidine in step four to give 6- (5- (2- ((S) -2- (1, 3-dimethyl-2, 6-dioxo-1, 2,3, 6-tetrahydro-7H-purin-7-yl) propanamido) thiazol-4-yl) pyrimidin-2-yl) -3, 6-diazabicyclo [3.1.1] heptane-3-carboxylic acid tert-butyl ester and removing the Boc protecting group with trifluoroacetic acid to give the title compound in yield: 56.2% and a purity of 98.94%.
ESI-MS:m/z= 509.2(M+H) + 。
1 H NMR(400 MHz, DMSO-d6) δ: 11.36 (s, 1H), 8.75 (s, 2H), 8.22 (d, 1H), 7.38 (s, 1H), 5.69(d, 1H), 4.43 (m, 2H), 3.46 (s, 3H), 3.38 (s, 3H) 3.16 – 3.02 (m, 4H), 2.71 – 2.63 (m, 1H), 2.19 (d, 1H), 2.04 (d, 1H), 1.67 (d, 3H)。
Example 17: preparation of (S) -2- (1, 3-dimethyl-2, 6-dioxo-1, 2,3, 6-tetrahydro-7H-purin-7-yl) -N- (4- (2- ((S) -3-methoxypyrrolidin-1-yl) pyrimidin-5-yl) -5-methylthiazol-2-yl) propanamide
Preparation method the same preparation method as in example 1 was followed by substituting equimolar 4-bromo-5-methylthiazol-2-amine for 4-bromothiazol-2-amine in step one and equimolar (S) -3-methoxypyrrolidine for (S) -2-methylpyrrolidine in step four to give the title compound in the yield: 43.6% and a purity of 97.26%.
ESI-MS:m/z= 526.2(M+H) + 。
1 H NMR (400 MHz, DMSO-d6) δ:11.30 (s, 1H), 8.69 (s, 2H), 8.22 (d, 1H), 5.68 (d, 1H), 4.39 (m,1H), 4.03 – 3.94 (m, 1H), 3.82 – 3.69 (m, 2H), 3.53 – 3.41 (m, 1H), 3.46 (s, 3H), 3.38 (s, 3H),3.20 (d, 3H), 2.48 (s, 3H), 2.08 – 1.96 (m, 1H),1.83 (m, 1H), 1.67 (d, 3H)。
Example 18: preparation of (S) -2- (1, 3-dimethyl-2, 6-dioxo-1, 2,3, 6-tetrahydro-7H-purin-7-yl) -N- (5-methyl-4- (2- ((S) -3- (trifluoromethoxy) pyrrolidin-1-yl) pyrimidin-5-yl) thiazol-2-yl) propanamide
Preparation method the same preparation method as in example 1 was followed by substituting equimolar 4-bromo-5-methylthiazol-2-amine for 4-bromothiazol-2-amine in step one and equimolar (S) -3-trifluoromethoxy pyrrolidine for (S) -2-methylpyrrolidine in step four to give the title compound in yield: 46.9% and 97.84% purity.
ESI-MS:m/z= 580.2(M+H) + 。
1 H NMR (400 MHz, DMSO-d6) δ:11.69 (s, 1H), 8.69 (s, 2H), 8.22 (d, 1H), 5.68 (d, 1H), 4.95 (m,1H), 4.08 (m, 1H), 3.88 – 3.75 (m, 2H), 3.53 – 3.43 (m, 1H), 3.46 (s, 3H), 3.38 (s, 3H), 2.48 (s, 3H), 2.14 – 2.03 (m, 1H), 1.85 (m,1H), 1.67 (d, 3H)。
Comparative example 1: preparation of N- (4- (2, 4-difluoro-3- (trifluoromethyl) pyrimidin-5-yl) thiazol-2-yl) -2- (1, 3-dimethyl-2, 4-dioxo-1, 2,3, 4-tetrahydrothiophene [2,3-d ] pyrimidin-5-yl) acetamide
Synthesized according to the method described in patent WO2013183035A2, purity: 98.9%.
ESI-MS:m/z= 517.1(M+H) + 。
1 H NMR (300 MHz, DMSO- d6) δ:3.19 (s, 3H), 3.46 (s, 3H), 4.07 (s, 2H), 7.07(s, 1H), 7.48-7.54 (t, 1H), 7.61 (s, 1H), 8.30-8.37 (q, 1H), 12.48 (br s, 1H)。
Comparative example 2: preparation of (S) -3- (3- (4-chlorobenzyl) -4- (4- (3-fluoropyridin-2-yloxy) pyrimidin-5-yl) amino) -2, 6-dioxa-3, 6-dihydropyrimidin-1 (2H) yl) -2-methylpropanoic acid
Synthesized according to the method described in patent WO2010075353A1, purity: 98.5%.
ESI-MS:m/z= 498.2(M+H) + 。
1 H NMR (400 MHz, DMSO-d6) δ: 12.87 (s, 1H), 8.03 (s, 1H), 7.68 (dd, 1H), 7.45 (dd, 1H), 7.42(s, 1H), 7.06 (dd, 1H), 5.32 (d, 2H), 3.71 – 3.60 (m, 2H), 3.46 (m, 4H), 3.38 (s, 3H), 1.96 – 1.82 (m, 1H), 1.87 – 1.72 (m, 2H),1.56 – 1.44 (m, 1H), 1.22 (d, 3H)。
Test example 1: cough test in mice
Test material for sexual function
Basic information of test article
The compounds of examples 1 to 18 (laboratory synthesis of the present invention), the compound of comparative example 1 (CRC 17536, positive control, laboratory synthesis of the present invention), and the compound of comparative example 2 (laboratory synthesis of the present invention).
Test reagent of the second aspect
Normal saline and ammonia water.
Sulfurus experimental animal
Healthy adult KM mice are male and female, 6 mice in each group, and the weight is about 28-30 g.
⒊ test method
The method comprises the steps of designing dosage and using amount of a sample
The animal cough model reported in the literature mostly adopts methods such as mechanical, chemical, electrical stimulation and the like to stimulate nerves and receptors of animals so as to cause cough. And (3) establishing a mouse cough modeling test by initially selecting a strong ammonia water induction method according to the characteristics of the candidate compound and the existing similar target compound as references.
Preparation method of test article
The preparation method of 50% ammonia water solution comprises the following steps: 2.5ml of ammonia water is measured and dissolved in 5ml of 0.9% sodium chloride injection, and the mixture is fully and uniformly mixed.
Comparative example 1 solution formulation method: 18mg of comparative example 1 was weighed and dissolved in 3ml of 0.5% CMC-Na solution, and the mixture was thoroughly mixed to prepare a solution of 6 mg/ml.
Comparative example 2 solution formulation method: 18mg of comparative example 2 was weighed and dissolved in 3ml of 0.5% CMC-Na solution, and the mixture was thoroughly mixed to prepare a solution of 6 mg/ml.
Example solution formulation method: 18mg of the examples were weighed into 3ml of 0.5% CMC-Na solution, and mixed well to prepare a solution of 6 mg/ml.
Experimental operation method
6 KM mice were taken per group: comparative example 1 group, comparative example 2 group, example group, model group. The mice of comparative example 1, comparative example 2 and example 1 were respectively given comparative example 1 compound (60 mg/kg), comparative example 2 compound (60 mg/kg) and example compound (60 mg/kg) by intragastric administration, and the model group was given an equal volume of 0.5% CMC-Na solution. After 30min of administration, the mice were placed in 500ml beakers, and 1 cotton ball (weight: 100.+ -. 5 mg) containing 0.3ml of 50% aqueous ammonia was placed in each beaker. Mice were observed for the number of typical coughs that occurred within 3min (typical coughing actions: abdominal muscle contraction or chest constriction, with simultaneous large mouth opening, with coughing).
⒋ results and discussion
Multi-level data processing system
(1) Cough criterion:
cough manifests as: the abdominal muscles contract or contract the chest, and simultaneously open the large mouth with cough.
(2) The number of coughs (times) in 3min of the mice was recorded by stopwatch, statistical analysis was performed by software, each group of data was statistically described by mean ± standard deviation, multi-group single factor analysis of variance was performed, and P <0.05 was statistically significant.
Discussion of results of the following
The cough times of the mice after 30min of administration of 60mg/kg of the compound of the examples are shown in the following table:
/>
note that: (1) * Representation P compared to model set<0.05； ** Representation P compared to model set<0.01； # Represents P compared with comparative example 1 group<0.05; (2) The compounds used in the group of comparative example 1 and the group of example 1 represent the compound of comparative example 1 and the compound of example 1, respectively, and the other are similarly explained.
As shown in the above table, the number of coughs was significantly reduced in the various example compounds of the present invention compared to the model group, and the number of coughs was significantly reduced in the example 1 group, the example 2 group, the example 3 group, the example 5 group, the example 6 group, and the example 12 group compared to the comparative example 1 group, and the number of coughs was also reduced and statistically significant compared to the comparative example 2 group.
Test example 2: serum biomarker study for rat hepatotoxicity
Test material for sexual function
Test article: compounds of examples 1,2,3, 5, 6, 12, 13 groups, compound of comparative example 2 (laboratory synthesis of the present inventors);
test reagent: 0.5% CMC-Na solution (lot number: G1226001).
Sulfurus experimental animal
Healthy adult SD rats weighing 180-200 g, 6-9 weeks of week old, total females, 6 animals per group.
⒊ test method
Preparation method of test piece
Example 5 group compound and comparative example compound formulation method: precisely weighing a proper amount of medicine, adding 0.5% CMC-Na, and mixing by ultrasonic and vortex; formulated to a drug concentration of 12.5 mg/ml.
Experimental operation method
The method comprises the steps of taking 6 healthy adult SD rats, after taking food overnight (free drinking), taking blank serum from jugular vein for 200 microliter blood supply biochemical detection, respectively carrying out tail vein injection after blood collection, carrying out single administration of 50mg/kg, observing and recording the toxic reaction condition and death condition of each rat after administration, taking blood again from jugular vein for 24 hours after administration, detecting blood biochemical indexes (AST and ALT), and placing the rats back to a feeder cage after blood collection is finished to continuously observe the condition after administration.
⒋ results and discussion
The blood biochemical index before and after administration of each group of rats was counted as shown in the following table: the blood biochemical indicators (AST, ALT) before and after administration of the mice in examples 1,2,3, 5, 6, 12 and 13 were not significantly changed, while the blood biochemical indicators (AST, ALT) 24h after administration of the mice in comparative example 2 were increased by 4.22 times and 9.52 times, respectively, relative to the mice before administration. The compounds of examples 1,2,3, 5, 6, 12 and 13 according to the present invention were shown to be safe without causing liver toxicity, which is significantly superior to the compound of comparative example 2.
The above embodiment is only one of the preferred embodiments of the present invention, and should not be used to limit the scope of the present invention, but all the insubstantial modifications or color changes made in the main design concept and spirit of the present invention are still consistent with the present invention, and all the technical problems to be solved are included in the scope of the present invention.
Claims (8)
1. A compound of formula (i) or a pharmaceutically acceptable salt thereof:
wherein ring a is selected from substituted or unsubstituted thiazole, or substituted or unsubstituted thiadiazole; the substituent of the ring A is selected from hydrogen or C1-C6 alkyl;
R 1 selected from C1-C3 perfluoroalkyl or from 1 to 2R 8 Substituted ring:
wherein each R 8 Independently selected from the group consisting of: C1-C6 alkyl or C1-C3 perfluoroalkyl.
2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R 8 Selected from the group consisting of: C1-C4 alkyl or C1-C3 perfluoroalkyl.
3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is:
4. the compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein hydrogen in the compound is substituted with one or more deuterium.
5. A pharmaceutical composition of a compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable adjuvant.
6. Use of a compound according to any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment and/or prevention of a disease associated with TRPA1 receptor.
7. The use according to claim 6, wherein the disease associated with TRPA1 receptor is selected from respiratory diseases.
8. The use according to claim 6, wherein the TRPA1 receptor related disease is selected from cough, asthma, pain or sleep apnea.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210448131.0A CN114671876B (en) | 2022-04-27 | 2022-04-27 | Novel theophylline compound, isomer or salt, preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210448131.0A CN114671876B (en) | 2022-04-27 | 2022-04-27 | Novel theophylline compound, isomer or salt, preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114671876A CN114671876A (en) | 2022-06-28 |
| CN114671876B true CN114671876B (en) | 2023-10-03 |
Family
ID=82080904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210448131.0A Active CN114671876B (en) | 2022-04-27 | 2022-04-27 | Novel theophylline compound, isomer or salt, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114671876B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014113671A1 (en) * | 2013-01-18 | 2014-07-24 | Cubist Pharmaceuticals, Inc. | Inhibiting the transient receptor potential a1 ion channel |
| CN106573934A (en) * | 2014-04-23 | 2017-04-19 | 海德拉生物科学公司 | Inhibiting the transient receptor potential A1 ion channel |
| CN106715430A (en) * | 2014-09-19 | 2017-05-24 | 海德拉生物科学公司 | Inhibiting the transient receptor potential A1 ion channel |
| CN111655693A (en) * | 2018-01-31 | 2020-09-11 | 伊莱利利公司 | Inhibition of transient receptor potential A1 ion channels |
-
2022
- 2022-04-27 CN CN202210448131.0A patent/CN114671876B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014113671A1 (en) * | 2013-01-18 | 2014-07-24 | Cubist Pharmaceuticals, Inc. | Inhibiting the transient receptor potential a1 ion channel |
| CN106573934A (en) * | 2014-04-23 | 2017-04-19 | 海德拉生物科学公司 | Inhibiting the transient receptor potential A1 ion channel |
| CN106715430A (en) * | 2014-09-19 | 2017-05-24 | 海德拉生物科学公司 | Inhibiting the transient receptor potential A1 ion channel |
| CN111655693A (en) * | 2018-01-31 | 2020-09-11 | 伊莱利利公司 | Inhibition of transient receptor potential A1 ion channels |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114671876A (en) | 2022-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020341681B2 (en) | RIP1 inhibitory compounds and methods for making and using the same | |
| RU2684641C1 (en) | Pyrazolopyridine derivatives as modulators of tnf activity | |
| JP2009528389A (en) | A2A adenosine receptor antagonist | |
| AU2020378407B2 (en) | Heterocyclic RIP1 inhibitory compounds | |
| TW200813064A (en) | Purinone derivatives as HM74A agonists | |
| CN111560012B (en) | Compound as IRAK inhibitor | |
| WO2016020288A1 (en) | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | |
| BR112016007563A2 (en) | thiazolopyrimidinones as modulators of nmda activity | |
| KR20130046436A (en) | Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same | |
| JP2021513519A (en) | Muscarinic acetylcholine receptor M4 antagonist | |
| JP2020530451A (en) | Antagonist of muscarinic acetylcholine receptor M4 | |
| ES2363672T3 (en) | TRIAZOLO [1,5-a] QUINOLINAS AS LIGANDS OF ADENOSINE A3 RECEIVER. | |
| CN111303133A (en) | Small molecule compound for degrading EZH2 protein | |
| JP2021513530A (en) | Tetrahydroisoquinoline compounds, methods of their preparation, pharmaceutical compositions containing such compounds and their use. | |
| CN114656472B (en) | Pyrazolopyrimidine compound, isomer or salt, and preparation method and application thereof | |
| CA3158731A1 (en) | Adenosine receptor antagonist compounds | |
| CN114671876B (en) | Novel theophylline compound, isomer or salt, preparation method and application thereof | |
| CN114656473B (en) | Pyrrolopyrimidine compound, isomer or salt, preparation method and application thereof | |
| CN114656480B (en) | Thienopyrimidine compound, isomer or salt, preparation method and application thereof | |
| CN114891003B (en) | Novel dihydropyrimidine compound, intermediate or salt, and preparation method and application thereof | |
| EP3976618A1 (en) | Tricyclic compounds | |
| JP2022549496A (en) | CRF receptor antagonists and methods of use | |
| TW202237101A (en) | Ctla-4 small molecule inhibitor and its application | |
| WO2022107044A1 (en) | Prevention and/or treatment of cns disorders | |
| EP4255893A1 (en) | Compounds and their use for treating neuropathic pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |